Wilmschen, SarahSarahWilmschenSchneider, SabrinaSabrinaSchneiderPeters, FelixFelixPetersBayer, LeaLeaBayerIssmail, LeilaLeilaIssmailBánki, ZoltánZoltánBánkiGrunwald, ThomasThomasGrunwaldLaer, Dorothee vonDorothee vonLaerKimpel, JanineJanineKimpel2022-03-062022-03-062019https://publica.fraunhofer.de/handle/publica/25858810.3390/vaccines7030059The respiratory syncytial virus (RSV) is one major cause of lower respiratory tract infections in childhood and an effective vaccine is still not available. We previously described a new rhabdoviral vector vaccine, VSV-GP, a variant of the vesicular stomatitis virus (VSV), where the VSV glycoprotein G is exchanged by the glycoprotein GP of the lymphocytic choriomeningitis virus. Here, we evaluated VSV-GP as vaccine vector for RSV with the aim to induce RSV neutralizing antibodies. Wild-type F (Fwt) or a codon optimized version (Fsyn) were introduced at position 5 into the VSV-GP genome. Both F versions were efficiently expressed in VSV-GP-F infected cells and incorporated into VSV-GP particles. In mice, high titers of RSV neutralizing antibodies were induced already after prime and subsequently boosted by a second immunization. After challenge with RSV, viral loads in the lungs of immunized mice were reduced by 2-3 logs with no signs of an enhanced disease induced by the vaccination. Even a single intranasal immunization significantly reduced viral load by a factor of more than 100-fold. RSV neutralizing antibodies were long lasting and mice were still protected when challenged 20 weeks after the boost. Therefore, VSV-GP is a promising candidate for an effective RSV vaccine.en610620journal article